Lexaria Bioscience Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments Significant Contracts and Contingencies (Tables)

Commitments Significant Contracts and Contingencies (Tables)

12 Months Ended

Aug. 31, 2022

Commitments Significant Contracts and Contingencies

Schedule of operating lease liabilities

		August 31, 2022				August 31, 2021
		$				$
Right of use assets - operating leases:			91,041				126,920
Amortization			(38,597	)			(35,879	)
Total lease assets			52,444				91,041
Liabilities:			89,393				125,431
Lease payments			(44,600	)			(43,950	)
Interest accretion			5,195				7,912
Total lease liabilities			49,988				89,393

Operating lease cost		$	52,444			$	91,041
Operating cash flows for lease		$	44,599			$	43,950
Remaining lease term			1.17 Years				2.1 Years
Discount rate			7.25	%			7.25	%

Schedule of maturities of operating lease liabilities

			$
2023			44,815
2024			7,469
Thereafter			-
Total lease payments			52,284
Less: imputed interest			(2,296	)
Present value of operating lease liabilities			49,988
Less: current obligations under leases			(42,587	)
Total			7,401